Literature DB >> 15247290

Diffuse pharmacophoric domains of vasoactive intestinal peptide (VIP) and further insights into the interaction of VIP with the N-terminal ectodomain of human VPAC1 receptor by photoaffinity labeling with [Bpa6]-VIP.

Yossan-Var Tan1, Alain Couvineau, Marc Laburthe.   

Abstract

The widespread 28-amino acid neuropeptide vasoactive intestinal peptide (VIP) exerts its many biological effects through interaction with serpentine class II G protein-coupled receptors named VPAC receptors. We previously provided evidence for a physical contact between the side chain at position 22 of VIP and the N-terminal ectodomain of the hVPAC1 receptor (Tan, Y. V., Couvineau, A., Van Rampelbergh, J., and Laburthe, M. (2003) J. Biol. Chem. 278, 36531-36536). We explored here the contact site between hVPAC1 receptor and the side chain at position 6 of VIP by photoaffinity labeling. The photoreactive para-benzoyl-l-Phe (Bpa) was substituted for Phe(6) in VIP resulting in [Bpa(6)]-VIP, which was shown to be a hVPAC1 receptor agonist in Chinese hamster ovary cells stably expressing the recombinant receptor. After obtaining the covalent (125)I-[Bpa(6)-VIP].hVPAC1 receptor complex, it was sequentially cleaved by cyanogen bromide, peptide N-glycosidase F, endopeptidase Glu-C, and trypsin, and the cleavage products were analyzed by electrophoresis. The data demonstrated that (125)I-[Bpa(6)-VIP] were covalently attached to the short 104-108 fragment within the N-terminal ectodomain of the receptor. The data were confirmed by creation of a receptor mutant with new CNBr cleavage site. In a three-dimensional model of the receptor N-terminal ectodomain, this fragment was located on one edge of the putative VIP-binding groove and was adjacent to the fragment covalently attached to the side chain at position 22 of VIP. Altogether these data showed that the central part of VIP, at least between Phe(6) and Tyr(22), interacts with the N-terminal ectodomain of the hVPAC1 receptor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15247290     DOI: 10.1074/jbc.M404460200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins.

Authors:  Alain Couvineau; Marc Laburthe
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  Structural and functional insights into the juxtamembranous amino-terminal tail and extracellular loop regions of class B GPCRs.

Authors:  M Dong; C Koole; D Wootten; P M Sexton; L J Miller
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

3.  Structure of the human glucagon class B G-protein-coupled receptor.

Authors:  Fai Yiu Siu; Min He; Chris de Graaf; Gye Won Han; Dehua Yang; Zhiyun Zhang; Caihong Zhou; Qingping Xu; Daniel Wacker; Jeremiah S Joseph; Wei Liu; Jesper Lau; Vadim Cherezov; Vsevolod Katritch; Ming-Wei Wang; Raymond C Stevens
Journal:  Nature       Date:  2013-07-17       Impact factor: 49.962

4.  The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics.

Authors:  Emilie Ceraudo; Samuel Murail; Yossan-Var Tan; Jean-Jacques Lacapère; Jean-Michel Neumann; Alain Couvineau; Marc Laburthe
Journal:  Mol Endocrinol       Date:  2007-09-20

5.  The N-terminal parts of VIP and antagonist PG97-269 physically interact with different regions of the human VPAC1 receptor.

Authors:  Emilie Ceraudo; Yossan-Var Tan; Pascal Nicole; Alain Couvineau; Marc Laburthe
Journal:  J Mol Neurosci       Date:  2008-07-03       Impact factor: 3.444

6.  Production and purification of large quantities of the functional N-terminal ectodomain of human VPAC1 receptor.

Authors:  Alain Couvineau; Jean-Claude Robert; Tarik Ramdani; Jean-Jacques Lacapère; Christiane Rouyer-Fessard; Marc Laburthe
Journal:  J Mol Neurosci       Date:  2008-07-01       Impact factor: 3.444

7.  The VPAC1 receptor: structure and function of a class B GPCR prototype.

Authors:  A Couvineau; E Ceraudo; Y-V Tan; P Nicole; M Laburthe
Journal:  Front Endocrinol (Lausanne)       Date:  2012-11-16       Impact factor: 5.555

Review 8.  Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.

Authors:  Yossan-Var Tan; James A Waschek
Journal:  ASN Neuro       Date:  2011-10-06       Impact factor: 4.146

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.